公开(公告)号：US20240051917A1

公开(公告)日：2024-02-15

申请号：US18197522

申请日：2023-05-15

Applicant: BIOGEN MA INC.

Inventor： Anton Fran Joseph FLIRI ,  Randall J. GALLUSCHUN ,  Christopher John O'DONNELL ,  Jacob Bradley SCHWARZ ,  Barbara Eileen SEGELSTEIN

IPC: C07C307/02 ,  C07C311/07 ,  C07D213/65 ,  C07D295/096 ,  C07D307/22 ,  C07D307/42 ,  C07D333/38 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D407/12 ,  C07D207/08 ,  C07D409/04

CPC classification number: C07C307/02 ,  C07C311/07 ,  C07D213/65 ,  C07D295/096 ,  C07D307/22 ,  C07D307/42 ,  C07D333/38 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D407/12 ,  C07D207/08 ,  C07D409/04 ,  C07C2601/08 ,  C07C2601/14

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I:




as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

公开(公告)号：US20240002356A1

公开(公告)日：2024-01-04

申请号：US18333454

申请日：2023-06-12

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D295/096 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4866 ,  A61K9/0053 ,  C07B2200/13

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARS agonist compound.

公开(公告)号：US11713301B2

公开(公告)日：2023-08-01

申请号：US17572037

申请日：2022-01-10

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana Del Rio Gancedo ,  Osama Suleiman ,  Emma Sharp ,  Cristina Balogh ,  Rachael Lee ,  Julie Macrae ,  Neil Feeder

IPC: A61K9/08 ,  C07D295/096 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D295/096 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4866 ,  C07B2200/13

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20230098332A1

公开(公告)日：2023-03-30

申请号：US17800049

申请日：2021-03-04

Applicant: Givaudan SA

Inventor： Nicolas COCITO ARMANINO ,  Julie CHARPENTIER ,  Chun CHEN ,  Changming DING ,  Roger EMTER ,  Andreas NATSCH ,  Chao WANG ,  Lijun ZHOU

IPC: C07D295/096 ,  C07D309/04 ,  C07D335/02 ,  C07D279/12 ,  C07D241/04

Abstract: Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucosa.

公开(公告)号：US20230051589A1

公开(公告)日：2023-02-16

申请号：US17293781

申请日：2019-11-14

Applicant: Novartis AG

Inventor： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, Jr. ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC: A61K31/426 ,  A61K45/06 ,  A61K31/64 ,  C07D307/64 ,  C07D277/36 ,  A61K31/381 ,  C07D333/34 ,  C07D409/12 ,  A61K31/4436 ,  A61K31/18 ,  C07C381/10 ,  C07D231/18 ,  A61K31/415 ,  A61K31/36 ,  A61K31/4406 ,  A61K31/47 ,  C07D317/62 ,  C07D213/71 ,  C07D215/36 ,  C07D487/04 ,  C07D405/12 ,  A61K31/4188 ,  A61K31/397 ,  C07D205/04 ,  C07D295/096 ,  A61K31/5375 ,  C07D207/10 ,  A61K31/40 ,  A61K31/4015 ,  C07D207/12 ,  C07D333/72 ,  A61K31/451 ,  C07D211/24 ,  C07D495/04 ,  A61K31/4365 ,  A61P1/00 ,  A61P37/06

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20220218713A1

公开(公告)日：2022-07-14

申请号：US17702304

申请日：2022-03-23

Applicant: NABRIVA THERAPEUTICS GMBH

Inventor： Rosemarie Mang ,  Werner Heilmayer ,  Rudolf Badegruber ,  Dirk Strickmann ,  Rodger Novak ,  Mathias Ferencic ,  Atchyuta Rama Chandra Murty Bulusu

IPC: A61K31/5375 ,  C07C323/52 ,  A61K31/215 ,  A61K31/357 ,  C07C323/61 ,  C07D295/096 ,  C07D317/72

Abstract: Pleuromutilin derivative compounds of the following formula (I), and uses thereof for the treatment of diseases mediated by microbes, are disclosed

公开(公告)号：US11186564B2

公开(公告)日：2021-11-30

申请号：US16322278

申请日：2016-08-04

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Scott P. Brown ,  Lee W. Herman

IPC: C07D211/22 ,  C07D401/08 ,  C07D401/14 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D471/04 ,  C07D487/10 ,  C07D491/107 ,  C07D311/22 ,  C07D217/24 ,  C07D223/08 ,  C07D235/12 ,  C07D237/14 ,  C07D413/06 ,  C07D241/04 ,  C07D243/08 ,  C07D471/08 ,  C07D491/048 ,  C07D267/10 ,  C07D275/04 ,  C07D211/58 ,  C07D403/06 ,  C07D405/12 ,  A61P25/28 ,  C07D417/04 ,  A61P25/18 ,  C07D513/04 ,  C07D211/42 ,  C07D295/104 ,  C07D207/36 ,  C07D213/81 ,  C07D491/20 ,  C07D249/12 ,  C07D221/20 ,  C07D295/088 ,  C07D311/58 ,  C07D207/12 ,  C07D211/44 ,  C07D265/30 ,  C07D277/66 ,  C07D295/027 ,  C07D295/073 ,  C07D295/096 ,  C07D295/108 ,  C07D307/83 ,  C07D311/08 ,  C07D413/08 ,  C07D471/10

Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

公开(公告)号：US20210332046A1

公开(公告)日：2021-10-28

申请号：US17370634

申请日：2021-07-08

Applicant: University of Florida Research Foundation, Inc.

Inventor： Nicole Alana Horenstein ,  Roger Lee Papke ,  Marta Quadri

IPC: C07D471/10 ,  A61K31/495 ,  A61K31/499 ,  A61K31/452 ,  A61K31/42 ,  C07D211/58 ,  C07D211/70 ,  C07D295/037 ,  C07D295/073 ,  C07D295/096 ,  C07D295/155

Abstract: Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

公开(公告)号：US11155551B2

公开(公告)日：2021-10-26

申请号：US16850408

申请日：2020-04-16

Applicant: University of Florida Research Foundation, Inc.

Inventor： Nicole Alana Horenstein ,  Roger Lee Papke ,  Marta Quadri

IPC: A61K31/495 ,  A61K31/452 ,  A61K31/499 ,  A61K31/42 ,  C07D471/10 ,  C07D211/58 ,  C07D211/70 ,  C07D295/037 ,  C07D295/073 ,  C07D295/096 ,  C07D295/155

Abstract: Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

公开(公告)号：US20210323913A1

公开(公告)日：2021-10-21

申请号：US16097171

申请日：2017-04-29

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Stephen F. MARTIN ,  James J. SAHN ,  Michael Dean WOOD

IPC: C07C271/24 ,  C07D207/27 ,  C07D233/61 ,  C07D295/096

Abstract: Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, traumatic brain injury, and neuropathic pain.